Liver-Kidney treatment response under review
NCT ID NCT06161766
First seen Dec 10, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This completed study from University Hospital Freiburg looked back at 490 patients with liver cirrhosis and signs of chronic kidney disease who were treated for hepatorenal syndrome. Researchers compared how well patients with and without pre-existing kidney disease responded to vasoactive drugs (terlipressin or noradrenalin) plus albumin. The goal was to understand treatment outcomes and help guide future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Münster
Münster, Germany
-
University Medical Center Freiburg
Freiburg im Breisgau, Germany
-
University Medical Center Mainz
Mainz, Germany
-
University Medical center Jena
Jena, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
terlipressin or noradrenalin plus albumin
What this could lead to
If successful, this could help doctors better identify which patients with liver and kidney problems are most likely to benefit from vasoactive treatment.
What could go wrong
This is a retrospective study, meaning it looks back at past data, so it cannot prove cause and effect. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.